

WHAT PATIENTS TOLD US ABOUT BIOMARKER TESTING IN NSCLC

Insights from 357 Patients and Caregivers Across 37 Countries

A global survey of people affected by non-small cell lung cancer (NSCLC) explored experiences, knowledge and needs related to biomarker testing



1 BIOMARKER TESTING HELPS GUIDE TREATMENT



95%

of patients and caregivers said biomarker test results were used to guide the choice of treatment

Biomarker testing helps doctors identify changes in a tumour that may influence treatment choices and help personalise care

2 BIOMARKER TESTING IS BECOMING ROUTINE

88%

of patients reported having biomarker testing performed



98% of those tested received biomarker testing at diagnosis

This shows that biomarker testing is increasingly recognised as an important part of NSCLC care

3 PATIENTS ARE STILL WAITING TOO LONG



1 in 4

waited more than 4 weeks to receive biomarker test results

Only **11%**

received results within the first week



Waiting for results can delay important treatment decisions and create uncertainty for patients and families

4 KNOWLEDGE IMPROVES AFTER TESTING



Before biomarker testing: **17%**

of patients considered themselves knowledgeable about biomarkers

After biomarker testing:

94%

of patients considered themselves somewhat or very knowledgeable

Patients and caregivers reported learning a great deal during the testing process, but many still wanted additional support and information

5 PATIENTS WANT MORE INFORMATION

The most commonly requested improvements by patients were:



Faster test results

60%

of patients



More information about biomarker testing

52%

of patients



Easier to understand information

48%

of patients

Patients and caregivers consistently highlighted the need for clear, timely and understandable communication

6 WHERE PATIENTS TURN FOR INFORMATION

When looking for additional information about biomarker testing, patients most often relied on:



Their healthcare team **73%**



Patient association or support groups **62%**



Online resources and social media **61%**



Other people living with lung cancer **45%**

This highlights the important role patient organisations play in supporting education and informed decision-making

Questions you can ask your healthcare team



- ✓ Has my tumour been tested for biomarkers, or will it be tested?
- ✓ Which biomarkers have been tested, or will be tested?
- ✓ What do my biomarker test results mean, or what information will they provide?
- ✓ How might my biomarker results affect my treatment options now or in the future?
- ✓ Can I receive a copy of my biomarker test report?

KEY MESSAGE:

Biomarker testing is essential for treatment decisions in NSCLC, but patients and caregivers need faster results, clearer information, and more support

^aSurvey conducted Jan-Apr 2024.

357 respondents in total (316 patients with NSCLC and 41 caregivers of people with NSCLC)
Abbreviations: NSCLC, non-small cell lung cancer. Reference: Biomarker Testing in NSCLC: Insights from Patients and Caregivers: <https://cor2ed.com/biomarker-testing-nsclc-survey>

Developed by experts from PRECISION ONCOLOGY CONNECT and LUNG CONNECT as an initiative of COR2ED. Supported by an Independent Educational Grant from Bayer



COR2ED
THE HEART OF MEDICAL EDUCATION

June 2026